47 results on '"Hughes, Dyfrig"'
Search Results
2. A proposal for using benefit-risk methods to improve the prominence of adverse event results when reporting trials
3. Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial
4. Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
5. The impact of parent treatment preference and other factors on recruitment: lessons learned from a paediatric epilepsy randomised controlled trial
6. Correction: Mechanistically informed non-invasive peripheral nerve stimulation for peripheral neuropathic pain: a randomised double-blind sham-controlled trial
7. Psychometric Properties of an Adapted Stigma Scale and Experiences of Stigma Associated with HIV Pre-exposure Prophylaxis Use Among Men Who have Sex with Men: A Mixed Methods Study
8. Between- and Within-Individual Sociodemographic and Psychological Determinants of PrEP Adherence Among Men Who have Sex with Men Prescribed a Daily PrEP Regimen in Wales
9. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
10. Health utilities and costs for neuromyelitis optica spectrum disorder
11. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
12. What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics
13. Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions
14. Utilising benefit-risk assessments within clinical trials—a protocol for the BRAINS project
15. Mechanistically informed non-invasive peripheral nerve stimulation for peripheral neuropathic pain: a randomised double-blind sham-controlled trial
16. The New and Non-Transparent Cancer Drugs Fund
17. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease
18. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes
19. CARer-ADministration of as-needed subcutaneous medication for breakthrough symptoms in homebased dying patients (CARiAD): study protocol for a UK-based open randomised pilot trial
20. Economic Studies in Motor Neurone Disease: A Systematic Methodological Review
21. Nerve root block versus surgery (NERVES) for the treatment of radicular pain secondary to a prolapsed intervertebral disc herniation: study protocol for a multi-centre randomised controlled trial
22. Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)
23. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions
24. A Systematic Review of Patients’ Perspectives on the Subcutaneous Route of Medication Administration
25. Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
26. Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria
27. Does Electronic Monitoring Influence Adherence to Medication? Randomized Controlled Trial of Measurement Reactivity
28. The trials and tribulations of accessing data from routine sources
29. Identification of items for a standardised resource-use measure: review of current instruments
30. Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation
31. Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis
32. Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity
33. Reimbursement Decisions of the All Wales Medicines Strategy Group: Influence of Policy and Clinical and Economic Factors
34. Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma
35. Value-Based Pricing: Incentive for Innovation or Zero Net Benefit?
36. Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations
37. Warfarin Pharmacogenetics: Economic Considerations
38. Feasibility, validity and reliability of the Welsh version of the EQ-5D health status questionnaire
39. When Drugs Don’t Work: Economic Assessment of Enhancing Compliance with Interventions Supported by Electronic Monitoring Devices
40. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease
41. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence
42. Clinical Pharmacology: Special Safety Considerations in Drug Development and Pharmacovigilance
43. Accounting for Noncompliance in Pharmacoeconomic Evaluations
44. Economic Evaluations During Early (Phase II) Drug Development: A Role for Clinical Trial Simulations?
45. Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?
46. Rationing of Drugs for Rare Diseases
47. A ‘steadiness’ factor for estimating the variability of residual drift in current meter records
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.